Stock Comparison
LLY vs VKTX
Eli Lilly and Co vs Viking Therapeutics Inc
Who's the better investment? Let's break it down.
The Verdict
VKTX takes this one.
It's not even close. VKTX outscores LLY by 8.4 points. That's a significant gap in our deep value framework.
Want to compare any two stocks?
Sign up free — get 3 DVR analyses/day, 1800+ stocks, portfolio roast. No credit card.
Valuation
LLY
Metric
VKTX
Market Cap
P/E Ratio
Lower may indicate better value
Price/Book
EV/EBITDA
Profitability & Growth
LLY
Metric
VKTX
Return on Equity
Return on Assets
EPS
Financial Health
LLY
Metric
VKTX
Current Ratio
Above 1.0 is healthy
Beta
Lower = less volatile
Dividend Yield
Risk Comparison
LLY
VKTX
What Could Go Wrong
The single biggest risk is a failure of VK2735 to replicate its positive Phase 2 efficacy or unexpected safety issues in its larger, longer Phase 3 trials. Such an outcome would eliminate the company'...
Red Flags
- 🚩Sustained widening of net losses beyond cash runway, leading to significant capital raise needs, bey...
- 🚩Unexpected clinical holds or significant delays in VK2735's Phase 3 trial initiation or progress, de...
- 🚩Key executives involved in VK2735 development departing unexpectedly, signaling potential internal i...
Competitive Moat
LLY
Rating
🛡️ Wide
Trend
📈 Expanding
VKTX
Rating
🛡️ Narrow
Trend
📈 Expanding
Investment Thesis
Eli Lilly is a pharmaceutical leader with a multi-decade growth runway, primarily driven by its innovative GLP-1 franchise (Mounjaro/Zepbound) and a robust pipeline in Alzheimer's and other high-demand therapeutic areas. Its strong R&D, manufacturing scale, and expanding market share position it for sustained, above-average growth within the healthcare sector, making it a core holding for long-ter...
Full LLY AnalysisIf VK2735 injectable demonstrates highly positive Phase 3 data (e.g., >15% weight loss at 68 weeks with strong safety profile), then the company could achieve an enterprise value reflecting a multi-billion dollar peak sales potential within 3-5 years. This is bullish because the current $3.8B market cap largely prices in Phase 2 success but leaves significant upside for Phase 3 de-risking and pote...
Full VKTX AnalysisPrice Targets & Strategy
Price Targets & Entry/Exit Strategy
Sign up free to unlock the full comparison
Growth Catalysts
Growth Catalysts Comparison
Sign up free to unlock the full comparison
Market Sentiment
Market Sentiment Analysis
Sign up free to unlock the full comparison
The Deep Dive
Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achieving a 10x return ($10 trillion+) within a 3-5 year timeframe fundamentally unrealistic. The major gr...
Full LLY AnalysisViking Therapeutics maintains strong 10x growth potential, with its lead asset VK2735 (a dual GLP-1/GIP agonist) continuing to show compelling clinical promise in the lucrative metabolic disorder market. Recent additional positive Phase 2 data for the oral formulation, showing up to 12.2% weight loss, reinforces its potential as a best-in-class option and strengthens its competitive position. While the Q1 2026 EPS miss and a significant 247% YoY increase in net loss to $158.3 million are financi...
Full VKTX AnalysisWant More Comparisons?
Run any stock through our deep value analyzer.
Not Financial Advice
This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified financial advisor before making investment decisions.